Supplementary Figures and Table from Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3–NANOG Axis

Supplementary Figure 1. SCP3 overexpression induces NANOG-mediated immune resistance and stem-like properties in human cancer cells. Supplementary Figure 2. MHC class I expression and CTL activation capacity of tumor cells are unaffected by SCP3 expression. Supplementary Figure 3. SCP3 expression in tumor cells does not control the viability of CTLs. Supplementary Figure 4. The SCP3 axis is conserved across various human cancer types. Supplementary Figure 5. CDK4/6 inhibitor is more effective than other drugs in SCP3-positive tumor cells. Supplementary Figure 6. Schematic interpretation of therapeutic resistance and tumorigenicity through the SCP3 axis.